Woburn, MA – November 23, 2010 – Aeris Therapeutics (www.aerist.com) received US Patent 7,819,908, entitled “Compositions and Methods for Reducing Lung Volume.” The patent includes broad claims related to the application of energy via a catheter as a method for non-surgical lung volume reduction. The patent enhances the company’s “best in class” intellectual property portfolio in the area of methods of treating emphysema.
About Aeris Therapeutics
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other advanced lung diseases. The company recently began commercialization of its lead product, the AeriSeal® System, in Europe. The AeriSeal System is intended to non-surgically reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema.
Founded in 2001, Aeris Therapeutics is privately held, with corporate offices in Woburn, MA.
Press Contact: David Dove, MD, MBA President & CEO (781) 937-0110 david.dove@aerist.com
